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Edited by Judit OvadiAbstract A thrombin-like enzyme of Bothrops atrox moojeni
venom, batroxobin, speciﬁcally cleaves ﬁbrinogen a chain,
resulting in the formation of non-crosslinked ﬁbrin clots. The
cDNA encoding batroxobin was cloned, expressed in Pichia
pastoris and the molecular function of puriﬁed recombinant
protein was also characterized. The recombinant batroxobin had
an apparent molecular weight of 33 kDa by SDS–PAGE
analysis and biochemical activities similar to those of native
batroxobin. The puriﬁed recombinant protein strongly converted
ﬁbrinogen into ﬁbrin clot in vitro, and shortened bleeding time
and whole blood coagulation time in vivo. However, it did not
make any considerable alterations on other blood coagulation
factors. Several lines of experimental evidence in this study
suggest that the recombinant batroxobin is a potent pro-
coagulant agent.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Snake venoms contain various components which aﬀect the
mammalian hemostatic system as either pro-coagulants or anti-
coagulants [1–3]. These components interact with diverse pro-
teins of the blood coagulation cascade and the ﬁbrinolytic
pathway [2,3]. Generally, they are classiﬁed into several groups
as follows: (i) ﬁbrinogen clotting enzymes; (ii) ﬁbrino(geno)lytic
enzymes; (iii) plasminogen activators; (iv) prothrombin
activators; (v) factor V, X activators, (vi) hemorrhagins; and
(vii) platelet aggregation inhibitors [3]. Thrombin-like enzymes,
which are serine proteases with ﬁbrinogen clotting activity,* Corresponding author. Fax: +82-2-365-1878.
E-mail address: khchung@yumc.yonsei.ac.kr (K.-H. Chung).
1 The ﬁrst two authors contributed equally to this work.
Abbreviations: APTT, activated partial thromboplastin time; PAS,
periodic acid-Schiﬀ’s reagent; PBS, phosphate-buﬀered saline; PCR,
polymerase chain reaction; PT, prothrombin time; SDS–PAGE,
sodium dodecyl sulfate–polyacrylamide gel electrophoresis; TT,
thrombin time
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doi:10.1016/j.febslet.2004.06.060have been identiﬁed and cloned from various snake venoms
[4,5]. Batroxobin (EC 3.4.21.29) was known to be a thrombin-
like enzyme from Bothrops atrox moojeni venom and its cDNA
was also cloned [6,7]. In contrast to thrombin, which converts
ﬁbrinogen into ﬁbrin by cleavage of ﬁbrinogen A and B chains,
batroxobin only splits oﬀ ﬁbrinopeptide A [6,7]. Additionally,
thrombin activates various blood coagulation proteins such as
factors V, VIII, and XIII as well as platelets, endothelial cells,
and smooth muscle cells which are closely related to hemostatic
system, whereas batroxobin has no direct eﬀects on these fac-
tors or cells [1]. The enzyme has a deﬁbrinogenating eﬀect and is
currently being used clinically for the treatment of various
thrombotic diseases including deep vein thrombosis, myocar-
dial infarction, pulmonary embolism, and acute ischemic stroke
[8–10].
Batroxobin contains 231 amino acids and 12 cysteine resi-
dues which are involved in six disulﬁde bonds. There are two
putative glycosylation sites in the polypeptide chain of bat-
roxobin [6,7,11]. Although recombinant thrombin-like en-
zymes of various snake venoms have been expressed in
Escherichia coli, these recombinant proteins usually formed
insoluble inclusion bodies [12–15]. It has proven diﬃcult to
refold inclusion bodies of thrombin-like enzymes as function-
ally active and soluble proteins [16,17].
In the present study, we report the cloning, expression and
functional characterization of recombinant batroxobin, a
snake venom thrombin-like enzyme, from Pichia pastoris. This
is the ﬁrst report demonstrating that the recombinant yeast-
produced batroxobin might be developed as a clinical pro-
coagulant agent for the treatment of thrombotic diseases.2. Materials and methods
2.1. Materials
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE) gel, molecular weight marker, and Pichia Expression Kit were
obtained from Invitrogen (Carlsbad, CA). Human ﬁbrinogen, throm-
bin, biotin, H-D-Ile-Phe-Lys-p-nitroanilide, N-Benzoyl-Phe-Val-Arg-p-
nitroanilide, and N-tosyl-Gly-Pro-Arg-p-nitroanilide were from Sigma
Chemical Co. (St. Louis, MO). H-D-Ile-Pro-Arg-p-nitroanilide (S-
2288), H-D-Phe-Pip-Arg-p-nitroanilide (S-2238), H-D-Pro-Phe-Arg-p-
nitroanilide (S-2302), and H-D-Val-Leu-Arg-p-nitroanilide (S-2266)
were from Chromogenix (Milano, Italy). Heparin–Sepharose and
Phenyl–Sepharose were products of Amersham Biosciences (Uppsala,
Sweden). Yeast nitrogen base was obtained from Becton Dickinsonation of European Biochemical Societies.
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Switzerland).
2.2. Construction of expression plasmid for batroxobin
The full-length cDNA of batroxobin (GenBank Accession
No. J02684) was kindly donated by Dr. Yamashina [7]. The cDNA
encoding batroxobin for yeast expression was cloned by polymerase
chain reaction (PCR) with the N-terminal primer 50-CTCGAGA-
AAAGAGTCATTGGAGGTGATG-30 and the C-terminal primer
50-TTCACGGGCTCGCAGTTTTATTTCCTGCAATAATGCTC-
30. The PCR product was cloned into pGEM-T Easy vector
(Promega, Madison, WI) and sequenced. The ampliﬁed cDNA of
batroxobin was transferred into P. pastoris expression vector,
pPIC9 (Invitrogen). The pPIC9-batroxobin vector was digested
with SalI (NEB, Beverly, MA) restriction enzyme. This linearized
plasmid was transformed into electro-competent GS115 cells
(Gene Pulser, Bio-Rad, Hercules, CA). Methanol utilization
ability of the Hisþ pPIC9-batroxobin transformants was analyzed
by replica selection on minimal dextrose and on minimal methanol
plate. Finally, Hisþ and Mutþ colony was selected for batroxobin
expression.
2.3. Expression of recombinant batroxobin by fermentation
Fermentation was performed using a BIOSTAT B fermenter (B.
Braun Biotech International, Melsungen, Germany) equipped with
software control (MFCS/Win 2.0) of temperature (30 C), agitation
(1000 rpm), pH, anti-foam addition, supplemental oxygen addition,
and feeding rate (glycerol and methanol). Stock cells were grown in
200 ml of yeast nitrogen base media for 24 h. The cultured cells were
transferred to a fermenter containing 1.5 liter of basal salt-glycerol
media (H3PO4, 27 ml/l; CaSO4  2H2O, 0.9 g/l; K2SO4, 18 g/l;
MgSO4  7H2O; 15 g/l, KOH, 4.13 g/l; and glycerol, 40 g/l) supple-
mented with 4.4 ml/l trace mineral solution. The pH of culture media
was maintained at 5.0 with 12.5% (w/v) NH4OH during fermentation.
Growth in batch mode was continued until the dissolved oxygen
concentration increased as a result of carbon source limitation (20 h).
A 50% glycerol containing 12 ml/l trace mineral solution and supple-
mental oxygen was automatically administered to maintain the dis-
solved oxygen concentration above 40% for 10 h. After carbon source
starvation (30 min) for complete glycerol consumption, methanol in-
duction was initiated. At the initiation of methanol feeding, feed rate
was lowered without oxygen supply (5 h) for adaptation of cells to
methanol. Methanol feeding (100% methanol containing 12 ml/l trace
mineral solution) was controlled by dissolved oxygen concentration
(above 40%). During the production phase (72 h), newly expressed
batroxobin was monitored by SDS–PAGE analysis.
2.4. Puriﬁcation and characterization of recombinant batroxobin
The batroxobin-expressed supernatant was collected by centrifuga-
tion. Ammonium sulfate was added to the supernatant to reach 2 M
and then was then loaded to a phenyl–Sepharose column followed by
elution with a gradient of 2–0 M ammonium sulfate. Recombinant
batroxobin fractions were further puriﬁed by heparin–Sepharose af-
ﬁnity chromatography. The recombinant protein was assayed by a
chromogenic synthetic substrate throughout the puriﬁcation proce-
dure. Puriﬁed recombinant protein was analyzed by SDS–PAGE. In
addition, N-terminal and internal amino acid sequences of re-
combinant batroxobin were analyzed by automated Edman degrada-
tion procedure and by MS/MS spectroscopy, respectively. The
glycosylation of recombinant and native batroxobins was examined by
PAS staining. To deglycosylate the proteins, denatured batroxobins
were incubated with N-glycosidase F (Roche Applied Science,
Mannheim, Germany) for 24 h at 37 C in 20 mM sodium phosphate
(pH 7.5). Deglycosylated batroxobins were analyzed by SDS–PAGE.
Western blotting was performed by using an anti-rabbit serum which
was obtained from native batroxobin-immunized rabbit. The immune
complex was visualized using chemiluminescence (Amersham Bio-
sciences).
2.5. Zymographic and ﬁbrinogen clotting assay
Zymographic assay was performed as previously described [18,19].
Recombinant and native batroxobins were electrophoresed on SDS–
PAGE under non-reducing conditions. To remove SDS, the gel was
soaked in an excess volume of 2.5% Triton X-100 for 20 min and then
washed four times with 20 mM Tris–HCl (pH 7.5) for 10 min. The gelwas then overlaid on a ﬁbrinogen (0.7%, w/v)-agarose (0.5%, w/v) plate
and incubated at 37 C. Fibrinogen clotting assay was measured as
previously described [20]. After recombinant and native batroxobins
were added to 0.5 ml of human ﬁbrinogen (0.5 mg/ml) in 20 mM Tris–
HCl (pH 7.5), clotting was monitored by changes in turbidity at
405 nm using a DU650 spectrophotometer (Beckman Coulter, Inc.
Chaska, MN).
2.6. Measurement of plasma clotting time in vitro
Rat plasma was obtained from whole blood by centrifugation. Re-
combinant and native batroxobins were treated in the plasma, and
then plasma clotting time was measured by using an Automated Co-
agulation Laboratory (ACL) 100 Instrument (Instrumentation Labo-
ratory Company, Milano, Italy).
2.7. Substrate speciﬁcity of batroxobin and thrombin
To investigate substrate speciﬁcity of recombinant batroxobin, na-
tive batroxobin, and thrombin, various synthetic substrates (100 lM)
were incubated with thrombin (60 nM) or each batroxobin (120 nM) in
0.2 ml of 20 mM Tris–HCl (pH 7.5). The hydrolytic reaction was
monitored at 405 nm by the formation of p-nitroaniline and lKat
value was calculated as described previously [21]. The chromogenic
substrates examined were: H-D-Ile-Phe-Lys-p-nitroanilide, N-Benzoyl-
Phe-Val-Arg-p-nitroanilide, N-tosyl-Gly-Pro-Arg-p-nitroanilide, H-D-
Ile-Pro-Arg-p-nitroanilide (S-2288), H-D-Phe-Pip-Arg-p-nitroanilide
(S-2238), H-D-Pro-Phe-Arg-p-nitroanilide (S-2302), and H-D-Val-Leu-
Arg-p-nitroanilide (S-2266).
2.8. Measurements of bleeding time and whole blood coagulation time
The bleeding time was measured as previously described [22].
Sprague–Dawley rats (n ¼ 5, 250–300 g) were pretreated by the
intravenous injection of recombinant and native batroxobins (1
NIH unit/kg) in phosphate-buﬀered saline (PBS). After 1 h, the tail
of rats was transfected at 5 mm from the tip and 1.5 cm of distal
portion was vertically immersed in PBS. The whole blood coagula-
tion time was measured by modiﬁed method in the previous report
[23]. Rats (n ¼ 5) were pretreated by intravenous injection of re-
combinant and native batroxobins (2 NIH unit/kg) in PBS. After 1 h,
the coagulation time of 0.5 ml citrated whole blood containing 10
mM CaCl2 was measured.
2.9. Measurements of coagulation parameters
The plasma clotting times, including activated thromboplastin time
(APTT), prothrombin time (PT), thrombin time (TT) and ﬁbrinogen
concentration, were measured as described previously [22,24]. Rats
(n ¼ 5) were pretreated by the intravenous injection of recombinant
and native batroxobins (0.1 NIH unit/kg) in PBS. After 2.5 h, the
batroxobin-treated plasma was obtained from rat citrated whole blood
by centrifugation. Then, coagulation parameters were measured by
using an ACL 100 Instrument.3. Results and discussion
3.1. Expression and puriﬁcation of recombinant batroxobin
Analysis of cDNA sequence encoding batroxobin revealed
that batroxobin is composed of 231 amino acids and 12 cy-
steines, which might be involved in six disulﬁde bonds
(Fig. 1A). A great number of disulﬁde bonds in the poly-
peptide chains are known to be signiﬁcant obstacles to refold
the recombinant proteins as active forms from insoluble in-
clusion bodies in E. coli [16,17]. It has also proven diﬃcult to
obtain recombinant thrombin-like enzymes as functionally
active proteins from E. coli-expression system. In this work,
however, recombinant batroxobin was successfully expressed
as a secretary recombinant protein in P. pastoris by methanol
induction (Fig. 2A, lane 1) and easily puriﬁed from the cul-
ture media by means of chromatographic fractionations (data
not shown). Initially, recombinant proteins in the cultured
media of P. pastoris containing 2 M ammonium sulfate were
1            11             21           31
Batroxobin      MVLIRVIANLLILQVSYAQKSSELVIGGDECDINEHPFLAFMY--YSPRYFCGMTLINQE
Trypsin         ------------------------IVGGYNCEENSVPYQVSLN---SGYHFCGGSLINEQ
Thrombin        ------------------------IVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDR
:: * :.: .  *: . :    . :** :**.:.
41                       51         61          71           81 
Batroxobin      WVLTAAHCN----------RRFMRIHLGKHAGSVAN-YDEVVRYPKEKFICPNKKKNVIT
Trypsin         WVVSAGHC--Y--------KSRIQVRLGEHNIEVLEGNEQFIN-AAKIIRHPQYD-RKTL
Thrombin        WVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENL
**::*.**           .  : :::*:*     :   : :    : *. . .   
91          101            111     121                131     
Batroxobin      DKDIMLIRLDRPVKNSEHIAPLSLP--SNPPS---VGSVCRIMGWGA-----ITTSEDTY
Trypsin         NNDIMLIKLSSRAVINARVSTISLP-TAPPAT----GTKCLISGWGN-----TASSGADY
Thrombin        DRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQ
:.** *::*.  .  .  : .:.**    ..:    *    : ***  :.     
141          151           161      171          181    
Batroxobin      PDVPHCANINLFNNTVCREAYNG-LPAKTLCAGVLQG--G-IDTCGGDSGGPLICNGQFQ
Trypsin         PDELQCLDAPVLSQAKCEASYPGKITSNMFCVGFLEG-GK--DSCQGDSGGPVVCNGQLQ
Thrombin        PSVLQVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFN
*.  :  :  :.... *. :    :. : :*.*   .     *:* ******.: :. :: 
191         201          211       221          231  
Batroxobin      ------GILSWGSDPCAEPRKPAFYTKVFDYLPWIQSIIAGNKTATCP
Trypsin         ------GVVSWG-DGCAQKNKPGVYTKVYNYVKWIKNTIAANS-----
Thrombin        NRWYQMGIVSWG-EGCDRDGKYGFYTHVFRLKKWIQKVIDQFGE----
*::*** : * .  * ..**:*:    **:. *
Amino acid sequencing of N-terminus and F4 fragment
F3 fragment
F1 fragment F2 fragment
1600 2000 2400 2800
m/z0
100
%
F2  2318.15 F4  2730.23
F3  2584.17
F1  1430.82
A
B
Fig. 1. Deduced amino acid sequence of batroxobin. (A) The deduced amino acid sequence from the cDNA of batroxobin (GenBank Accession No.
J02684) is denoted by one-letter symbols and aligned with those of other serine proteases. The zymogen peptide is shown in italics. Two putative
glycosylation sites are underlined. Amino acid sequences determined by Edman degradation and MS/MS spectroscopy are underlined with dashes.
The primary (S1), secondary (S2) and tertiary (S3) speciﬁcity sites of each protease are shown in bold-faced type. The amino acids of S1 loop in
thrombin are boxed. (B) MS spectrum of trypsinized-recombinant batroxobin is shown. The internal amino acid sequences of several peptide
fragments (F1–F4) were analyzed and the observed mass of each peptide fragment is also shown.
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linear gradient of ammonium sulfate. Recombinant batrox-
obin fractions were pooled and dialyzed against 20 mM Tris–
HCl (pH 7.0) buﬀer, and were then further puriﬁed by using
a heparin–Sepharose aﬃnity column with a linear gradient of
0–0.5 M NaCl.While native batroxobin migrated as a molecular weight of
37 kDa, puriﬁed recombinant batroxobin migrated as an ap-
parent molecular weight of 33 kDa in SDS–PAGE (Fig. 2A,
lanes 3 and 4). Such a diﬀerence in protein mobility may be due
to the distinct glycosylation system between yeast and snake.
The carbohydrate content of thrombin-like enzymes varies
Fig. 2. Characterization of recombinant batroxobin from P. pastoris.
(A) Recombinant batroxobin was expressed from P. pastoris by
methanol induction. Culture media induced by methanol for 72 h were
precipitated with 20% trichloroacetic acid and then analyzed by a 4–
20% gradient SDS–PAGE (lane 1). Recombinant batroxobin fraction
of phenyl–Sepharose (lane 2), puriﬁed recombinant batroxobin (lane
3), and native batroxobin (lane 4) were also analyzed by the SDS–
PAGE. Both batroxobins were stained with PAS reagent (lanes 5 and
6) and deglycosylated batroxobins by N-glycosidase migrated as a
molecular weight of 26 kDa (lanes 7 and 8). (B) Recombinant bat-
roxobin (lane 1) was also reacted with anti-native batroxobin serum.
(C) Recombinant batroxobin (lane 1) and native batroxobin (lane 2)
converted ﬁbrinogen into ﬁbrin, which results in the formation of
turbid band on the ﬁbrinogen-agar plate.
70 W.-K. You et al. / FEBS Letters 571 (2004) 67–73also considerably depending on snake species and it is re-
sponsible for the diﬀerent molecular mass of these proteins [3].
PAS staining result indicated that recombinant and native
batroxobins are glycoproteins (Fig. 2A, lanes 5 and 6), which
have two putative glycosylation sites in the polypeptide chain
(Fig. 1A). Native batroxobin is known to be containing about
40 diﬀerent oligosaccharide subfractions including a unique
oligosaccharide pattern of snake venom [11], whereas re-
combinant batroxobin expressed from P. pastoris might be
containing the yeast-type carbohydrate structures [25]. When
the covalently attached carbohydrate structures were removed
from both proteins by N-glycosidase treatment, recombinant
and native deglycosylated batroxobins migrated as a smaller
molecular size corresponding to 26 kDa (Fig. 2A, lanes 7 and
8), which is consistent from that of the calculated molecular
weight (25504.3) based on the cDNA-deduced amino acids of
batroxobin. The N-terminal and internal amino acid sequencesTable 1
Puriﬁcation of recombinant batroxobin from 1 liter of P. pastoris culture m
Puriﬁcation step Total protein
(mg)
Total activity
(NIH units)
Sp
(N
Culture media 178.75 3430.98 1
Phenyl–Sepharose 61.10 3127.38 5
Heparin–Sepharose 6.95 1825.28 26of recombinant batroxobin were also found to be identical to
the deduced polypeptide sequence (Fig. 1). Finally, 7 mg of
recombinant batroxobin was puriﬁed with a yield of 53.2%
from 1 liter fermentation media (Table 1). Western blot anal-
ysis demonstrated that yeast-derived recombinant batroxobin
as well as native protein speciﬁcally reacted with anti-native
batroxobin rabbit serum (Fig. 2B).
3.2. In vitro ﬁbrinogen clotting activity of recombinant
batroxobin
The functional activity of recombinant batroxobin was ex-
amined by using zymography assay and ﬁbrinogen polymeri-
zation assay. Under non-reducing conditions, recombinant
and native batroxobins were able to form turbid bands cor-
responding to their molecular sizes on the ﬁbrinogen-agar
plate (Fig. 2C). Additionally, in vitro ﬁbrinogen clotting assay
demonstrated that both batroxobins converted ﬁbrinogen into
ﬁbrin clot (Fig. 3A). To perform exact and quantitative anal-
ysis of batroxobin clotting activity, plasma clotting time was
measured with batroxobin-treated plasma in vitro by using an
ACL 100 Instrument. Both recombinant and native batroxo-
bins were able to coagulate plasma in a dose-dependent
manner, and the activity of puriﬁed recombinant batroxobin
fraction was more powerful than that of native protein fraction
(Fig. 3B). As shown in Fig. 2A, the purity of recombinant
batroxobin is much higher than that of native protein and it
may be responsible for stronger activity of recombinant pro-
tein than native protein fraction.
3.3. Substrate speciﬁcity analysis
To compare substrate speciﬁcity of recombinant, native
batroxobin and thrombin, various synthetic chromogenic
substrates were reacted with each enzyme. The substrate
speciﬁcity of recombinant batroxobin was similar to that of
native protein (Fig. 3C). Generally, both thrombin and bat-
roxobin preferentially hydrolyze arginine over lysine at the
peptide bond cleavage site [26]. However, the substrate speci-
ﬁcity of batroxobin was remarkably diﬀerent with that of
thrombin [26]. Although thrombin demonstrated a strong
hydrolyzing activity on the substrates, which have proline at
the P2 position, recombinant and native batroxobins showed
less eﬀective activities on these substrates. In case of the sub-
strate containing leucine at the P2 position, such as S-2266,
batroxobin had more powerful activity than that of thrombin
(Fig. 3C). As demonstrated in Fig. 1A, batroxobin has the
primary (S1), secondary (S2) and tertiary (S3) speciﬁcity sites
(Asp172, Gly195, and Ala206) similar to those of thrombin and
trypsin, allowing the large substrate side chain access to the
base of the catalytic site of enzyme [27,28]. However, batrox-
obin primary structure lacks amino acid residue insertions
around the active site cleft (S1 loop) in comparison to
thrombin (segment Lys-Arg-Gly, boxed amino acids inedia
eciﬁc activity
IH units/mg)
Puriﬁcation fold Puriﬁcation yield (%)
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Fig. 3. Fibrinogen clotting activity and substrate speciﬁcity of batrox-
obin. (A) Both recombinant and native batroxobins converted ﬁbrino-
gen into ﬁbrin clot in vitro. (B) Both batroxobins were also able to clot
plasma in a dose-dependent manner. (C) The catalytic activity of
thrombin and both batroxobins wasmeasured by using several synthetic
substrates, including H-D-Val-Leu-Arg-p-nitroanilide (S-2266), H-D-
Pro-Phe-Arg-p-nitroanilide (S-2302), H-D-Phe-Pip-Arg-p-nitroanilide
(S-2238), H-D-Ile-Pro-Arg-p-nitroanilide (S-2288), N-tosyl-Gly-Pro-
Arg-p-nitroanilide (T1637, SigmaCat. No.),N-Benzoyl-Phe-Val-Arg-p-
nitroanilide (B7632, Sigma), andH-D-Ile-Phe-Lys-p-nitroanilide (I6886,
Sigma). Data were expressed as meansS.E.M. from three separate
experiments.
0
20
40
60
80
100
120
0
100
200
300
400
PBS native
Batroxobin
recombinant
Batroxobin
PBS native
Batroxobin
recombinant
Batroxobin
Ti
m
e 
(se
c)
Ti
m
e 
(se
c)
A
B
Fig. 4. Eﬀects of batroxobin on in vivo bleeding time and whole blood
coagulation time. Both recombinant and native batroxobins reduced
rat tail bleeding time (A) and whole blood coagulation time (B). Rats
(n ¼ 5, 250–300 g) were pretreated by the intravenous injection of re-
combinant and native batroxobins (1 NIH unit/kg) in PBS. After 1 h,
the bleeding time and the whole blood coagulation time were measured
as described in Section 2.
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key residues aﬀecting snake protease speciﬁcity for the P2
subsite [29]. These regions of batroxobin are composed of
more non-polar and smaller amino acids than thrombin. Such
diﬀerent structural motifs can be responsible for the distinction
of substrate speciﬁcity between batroxobin and thrombin.
Thrombin-like enzymes of venombin A class, including an-
crod, batroxobin, and crotalase, are known to cleave the
Arg16–Gly17 peptide bond in the Aa-chain of ﬁbrinogen
leading to the release of ﬁbrinopeptide A and the conversion ofﬁbrinogen into a ﬁbrin clot [3]. However, thrombin cleaves not
only the Arg16–Gly17 peptide bond in the Aa-chain but also
the Arg14–Gly15 peptide bond in the Bb-chain, releasing ﬁ-
brinopeptide A and ﬁbrinopeptide B from ﬁbrinogen [30].
Speciﬁcally, residues 194–196 are known to be an important
region in regulating the interaction of thrombin with ﬁbrino-
gen. The mutation of these residues in thrombin compromises
the pro-coagulant activity up to 500-fold [27,31]. While resi-
dues Trp194 and Gly195 are strictly conserved in thrombin and
thrombin-like enzymes (Fig. 1A), residue Ser196 is widely di-
verse in thrombin-like enzymes. Mutant studies on these
functionally important amino acid residues of batroxobin will
be valuable for understanding the diﬀerent substrate speciﬁcity
between thrombin and thrombin-like enzymes.
Although most snake venom serine proteases demonstrate
signiﬁcant similarities of the primary structures, they are
known to have various and distinct eﬀects on the hemostatic
system, for example, ﬁbrino(geno)lysis, ﬁbrinogen clotting,
plasminogen activating, and activation of other coagulation
factors [1–3]. Even thrombin-like enzymes showed diﬀerent
substrate speciﬁcities on ﬁbrinogen according to their classiﬁ-
cation [3]. The venombin A class hydrolyzes ﬁbrinogen a-chain
and releases ﬁbrinopeptide A preferentially, and the venombin
AB class releases both ﬁbrinopeptides A and B. The third class
of thrombin-like enzyme, venombin B, had preferential hy-
drolytic activity on ﬁbrinogen b-chain. However, the struc-
ture–function relationships related with the molecular
structure and substrate speciﬁcity of thrombin-like enzymes
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Fig. 5. In vivo eﬀects of batroxobin on coagulation parameters. Eﬀects of both batroxobins on activated partial thromboplastin time, APTT (A),
prothrombin time, PT (B), thrombin time, TT (C) and ﬁbrinogen concentration in rat plasma (D) were examined. Rats (n ¼ 5) were pretreated by the
intravenous injection of recombinant and native batroxobins (0.1 NIH unit/kg) in PBS. After 2.5 h, the batroxobin-treated plasma was obtained from
rat citrated whole blood by centrifugation. Then, coagulation parameters were measured by using an ACL 100 Instrument.
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Ala-scanning mutagenesis studies based on our expression
system will be useful tools to investigate the structure–function
relationships of thrombin-like enzymes.
3.4. Eﬀects on bleeding time and whole blood coagulation time
in vivo
To examine the pro-coagulant activity of the recombinant
batroxobin in vivo, bleeding time and whole blood coagulation
time were measured by using rats which were administered
with recombinant and native batroxobins. As shown in Fig. 4,
recombinant and native batroxobins were capable of reducing
the tail bleeding time and whole blood coagulation time. Based
on these experimental results, it is possible to suggest that re-
combinant batroxobin is able to form clottable ﬁbrinogen in
whole blood and to shorten bleeding time as a pro-coagulant
agent in vivo.
3.5. Eﬀects of recombinant batroxobin on coagulation
parameters
To investigate whether the recombinant batroxobin has an
inﬂuence on other blood coagulation factors in vivo, the co-
agulation parameters, including APTT, PT, and TT, were
measured with batroxobin-treated rat plasma. The coagulation
parameters were not signiﬁcantly aﬀected by the treatments of
both batroxobins (Fig. 5A–C). However, these parameters
tended to slightly decrease. Experimental data of coagulation
parameters analysis demonstrated that recombinant batroxo-
bin has no signiﬁcant inﬂuence on other coagulation factors.
Snake venom thrombin-like enzymes such as batroxobin,
crotalase and ancrod were known to have not only potent pro-
coagulant activities but also deﬁbrinogenating activities, whichare associated with the reduction of ﬁbrinogen level in plasma
by clearing converted ﬁbrinogen and enhancing ﬁbrinolytic
activity [9,10,32–34]. Recombinant and native batroxobins
also decreased ﬁbrinogen concentration in rat plasma
(Fig. 5D), which might be closely correlated with slight re-
ductions of coagulation parameters including APTT, PT, and
TT.
In this work, the recombinant batroxobin, a snake venom
thrombin-like enzyme of Bothrops atrox moojeni, was suc-
cessfully expressed and puriﬁed from P. pastoris by high den-
sity fermentation. Here, we report that the molecular functions
of recombinant batroxobin were also characterized and com-
pared to its native protein. Several lines of experimental results
in this study suggest that the recombinant batroxobin has a
potent pro-coagulant activity in vitro and in vivo assay sys-
tems. Since the coagulation studies on reptilase in the 1950s
[35], thrombin-like enzymes have been extensively studied be-
cause of their potential therapeutic use in various thrombotic
diseases, and some enzymes have been used in the prevention
of thrombus formation and in improving the blood circulation
by reducing blood viscosity [8–10]. Native batroxobin also has
a good therapeutic eﬀect in ischemic reperfused rats and is a
good reagent used in quantitative determination of ﬁbrinogen,
especially in the plasma patients under heparin treatment [32].
The recombinant batroxobin in this work is the ﬁrst highly
active and pure recombinant snake venom thrombin-like en-
zyme, which might be developed as a clinical agent in sub-
stitute for native protein. In aspects of basic research, the
experimental results and data of recombinant batroxobin will
make it possible to study structure–function relationships of
thrombin-like enzymes as well as other snake venom serine
proteases acting on mammalian hemostasis.
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